MiR-18a-3p improves cartilage matrix remodeling and inhibits inflammation in osteoarthritis by suppressing PDP1

Osteoarthritis (OA) is a degenerative disease characterized by synovial inflammation. MiR-18a-3p was reported to be downregulated in knee anterior cruciate ligament of OA patients. In the present study, the specific functions and mechanism of miR-18a-3p in OA were explored. An in vitro model of OA was established using 10 ng/ml IL-1β to treat ATDC5 cells, and medial meniscus instability surgery was performed on Wistar rats to establish in vivo rat model of OA. RT-qPCR revealed that miR-18a-3p was downregulated in IL-1β-stimulated ATDC5 cells. MiR-18a-3p overexpression inhibited secretion of inflammatory cytokines and concentration of matrix metalloproteinases, as shown by ELISA and western blotting. The binding relation between miR-18a-3p and pyruvate dehydrogenase phosphatase catalytic subunit 1 (PDP1) was detected by luciferase reporter assays. MiR-18a-3p targeted PDP1 and negatively regulated PDP1 expression. Results of rescue assays revealed that PDP1 upregulation reserved the suppressive effect of miR-18a-3p overexpression on levels of inflammatory cytokines and matrix metalloproteinases in IL-1β-stimulated ATDC5 cells. H&E staining was used to observe pathological changes of synovial tissues in the knee joint of Wistar rats. Safranin O-fast green/hematoxylin was used to stain cartilage samples of knee joints. MiR-18a-3p overexpression suppressed OA progression in vivo. Overall, miR-18a-3p improves cartilage matrix remodeling and suppresses inflammation in OA by targeting PDP1. Supplementary Information The online version contains supplementary material available at 10.1186/s12576-022-00827-3.


Introduction
Osteoarthritis (OA) is an articular joint disease with high morbidity in the elderly people [1]. From 2005 to 2015, approximately 200 million of people were afflicted with OA, 2% of whom suffered from physical disability [2]. The etiological factors of OA include obesity, heredity, cardiovascular diseases, aging, genetic factors and joint injury [3]. OA is attributed to premature onset of OA after joint injury [4]. Clinically, the manifestation of OA includes narrowing of the joint space, emergence of osteophytes through osteoarthritic remodeling, cartilage erosion, and fibrillation [5]. In recent years, mounting medical expenditures used for OA treatment have brought a burden on OA patients and the whole society [6]. Therefore, there is an urgent need to look for an effective therapy of OA.
The main pathological changes of OA are articular cartilage degeneration, inflammation of synovitis, and secondary bone hyperplasia [7,8]. Cartilage, a connective tissue with high specialization, is composed of chondrocytes and extracellular matrix [9]. Chondrocytes synthesize extracellular matrix to maintain the structural and functional integrity of the cartilage [10]. However, chondrocytes are difficult to maintain cartilage homeostasis in response to OA stimulation [11]. Chondrocytes convert to catabolic cells that secrete matrix-degrading enzymes, such as matrix metalloproteinases (MMPs), and cartilage degeneration was induced when catabolic-degrading effects overwhelm the anabolic-protective function in OA chondrocytes [10]. Chondrocyte catabolism can be stimulated by inflammatory cytokines including tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β) and prostaglandin E2 (PGE2) [10]. TNF-α, for example, can induce the expression of proteases such as MMP1, MMP2, MMP3, MMP8, MMP9, MMP14, ADAMTS-4 and ADAMTS-5 [12]. Many previous studies also verified that inflammation in the synovitis is a key factor leading to OA progression [10,13,14]. MicroRNAs (miRNAs) are noncoding RNAs with 22-25 nucleotides in length [15]. The involvement of miRNAs in OA was reported in numerous studies [16]. For example, miR-485-3p regulates the Notch2/NF-κB pathway to inhibit apoptosis and promote chondrocyte proliferation in OA [17]. MiR-132 upregulation facilitates the proliferative ability and suppresses the apoptosis of chondrocytes in OA by modulating the PTEN/ PI3K/AKT signaling pathway [18]. Overexpressed miR-144-3p reduces the numbers of IL-1β-positive cells in synovial tissue to ameliorate OA pathogenesis [19]. MiR-18a-3p was reported to be downregulated in knee anterior cruciate ligament of OA patients [20]. Additionally, miR-18a-3p targets HOXA1 to induce apoptosis of chondrocytes in OA [21]. Although miR-18a-3p can participate in OA pathogenesis, its effects on cartilage matrix remodeling and inflammation in OA are still unknown.
In this study, we explored the functional role of miR-18a-3p in cartilage matrix deposition and inflammatory response of chondrocytes in OA and investigated the underlying mechanism of miR-18a-3p. The study may help us understand the molecular mechanism underlying OA development and provide insight into effective therapies for OA patients.

Establishment of OA animal model
A total of 32 Wistar rats (male, 8-week-old) were obtained from the Jackson Laboratory (USA) and were randomly divided into four groups: sham + AAV-miR-NC, sham + AAV-miR-18a-3p, OA + AAV-miR-NC and OA + AAV-miR-18a-3p. Each group has 8 rats. All rats were kept in a pathogen-free environment, and all operations were performed under isoflurane anesthesia, with all efforts made to minimize suffering. In OA group, rats were performed medial meniscus instability surgery on the right knee after anesthetization with isoflurane to induce joint instability and posttraumatic OA. Rats in sham group received similar surgical procedure without removing the ligament or meniscus. After surgery, AAV-miR-NC and AAV-miR-18a-3p were injected into OA rats or sham-operated rats. After 8 weeks, all rats were euthanized. Then, synovial tissues, cartilage tissues and blood samples were collected. All animal experiments were approved by the Animal Care and Use Committee of Changzhou Cancer Hospital Affiliated to Soochow University (Jiangsu, China) and performed in accordance with the committee's guidelines.

Cell transfection
MiR-18a-3p mimics was used to overexpress miR-18a-3p and the negative control (NC) was named as miR-NC. Full-length sequence of pyruvate dehydrogenase phosphatase catalytic subunit 1 (PDP1) was subcloned into the pcDNA3.1 vector to elevate PDP1 expression with pcDNA3.1 as a control. All plasmids were constructed by Genepharma (Shanghai, China). Cell transfection was conducted using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer's protocols, and the transfection efficiency was examined using reverse transcription quantitative polymerase chain reaction (RT-qPCR) after 48 h.

Hematoxylin-eosin (H&E) staining
First, synovial tissues collected from sham-operated control rats and OA rats were fixed with paraformaldehyde, dehydrated, paraffin-embedded, and sliced into sections. After that, H&E was used to stain the tissues. A microscope was used to observe pathological changes of synovial tissues. The standard of pathological score was set as previous described [22]. Higher score represented greater joint injury severity.

Safranin O/fast green staining
Knee joints of sham-operated control rats and OA rats were deparaffinized in xylene, hydrated with gradient ethanol, and stained with safranin-O/fast green. Scoring criteria was introduced in this study [23].

Enzyme-linked immunosorbent assay (ELISA)
For in vitro experiments, ATDC5 cells (2 × 10 5 cells/well) were pretreated with different vectors in 6-well plates for 2 h and then stimulated with IL-1β. For in vivo experiments, blood samples were collected from rats infected with AAV. Then, serum was obtained after blood samples were centrifuged at 6000×g for 15 min at 4 °C. The concentrations of inflammatory cytokines (IL-6, IL-8 and PGE2) in cells or serum were assessed using corresponding ELISA kits (Elabscience Biotechnology, Wuhan, China). Absorbance values were read at 450 nm in a microplate reader (BioTek synergy HT, Bedfordshire, UK).

RT-qPCR
After transfection, the total RNA was extracted from ATDC5 cells and tissues of OA rats using TRIzol reagent (Invitrogen). Total RNA was reverse transcribed into cDNA utilizing a PrimeScript product RT reagent Kit (Takara, Kyoto, Japan). Then, cDNA was amplified by polymerase chain reaction (PCR). U6 was the internal reference of miR-18a-3p and GAPDH was the internal reference of mRNAs. The results were analyzed using the 2 −ΔΔCt method. The primer sequences are presented in Additional file 1: Table S1.

Statistical analysis
The data are presented as the mean ± standard deviation and statistics were analyzed by GraphPad Prism software 6.0 (La Jolla, CA, USA). Student's t test was utilized for difference comparison between two groups, and one-way analysis of variance followed by Tukey's post hoc analysis were used for evaluation of differences among multiple groups. A value of p < 0.05 was considered statistically significant.

MiR-18a-3p overexpression improves cartilage matrix remodeling and inflammation in an in vitro model of OA
First, we used IL-1β to stimulate ATDC5 cells to construct an in vitro model of OA. After IL-1β treatment, we observed that miR-18a-3p expression in ATDC5 cells was downregulated (Fig. 1A). miR-18a-3p expression was increased in ATDC5 cells after transfection with miR-18a-3p mimic (Fig. 1B). Then, secretion of inflammatory cytokines including IL-8, IL-6 and PGE2 was examined by ELISA. The results showed that IL-1β increased the release of these inflammatory cytokines in ATDC5 cells, and miR-18a-3p overexpression reversed IL-1β-induced increase in cytokines ( Fig. 1C-E). Meanwhile, the protein levels of matrix metalloproteinases (MMP2, MMP3, and MMP9) were increased in ATDC5 cells after IL-1β treatment compared with those in control groups and were decreased in IL-1β-stimulated ATDC5 cells silencing miR-18a-3p compared with those in cells transfected with miR-NC (Fig. 1F). All these data suggested that an in vitro model of OA was successfully established. In addition, miR-18a-3p is downregulated in IL-1βstimulated ATDC5 cells, and miR-18a-3p overexpression suppress levels of matrix metalloproteinases and proinflammatory cytokines in the in vitro model of OA.

Discussion
OA is a degenerative disease that poses a threat to health condition of humans [24]. IL-1β can induce articular chondrocytes to produce cytokines and chemokines, thus leading to inflammation [25]. IL-1β upregulates MMPs to damage articular cartilage structure and unbalance metabolism [26]. Thus, IL-1β overexpression is a hallmark of OA progression [27]. In this study, IL-1β was used to treat ATDC5 cells to stimulate the in vitro pathological environment of OA. After IL-1β stimulation, the secretion of inflammatory cytokines (IL-8, IL-6 and PGE2) and the concentration of matrix metalloproteinases (MMP2, MMP3 and MMP9) were increased in ATDC5 cells. The results suggested that an in vitro model of OA was successfully established.
Accumulating studies have revealed that miRNAs are involved in OA progression [16,28,29]. In the current study, miR-18a-3p was downregulated in an in vitro model of OA, suggesting that miR-18a-3p participated in the pathogenesis of OA. MiR-18a-3p was reported to be downregulated in the knee anterior cruciate ligament of OA patients [20], which is consistent with our results. However, in another study, miR-18a-3p was reported to be upregulated in chondrocytes isolated from mouse and human cartilage tissues and directly target downstream gene homeobox A1 to facilitate chondrocyte apoptosis [21], which is opposite to our findings and the results of miRNA sequencing done by Bin et al. [20]. Furthermore, miR-18a, also termed miR-18a-5p, is derived from the same pri-miRNA as miR-18a-3p. MiR-18a-5p is overexpressed in primary Sjögren's syndrome, a disease that can cause muscle and joint pain and muscle weakness [30]. MiR-18a-5p increased the expression of MMP1, inflammatory cytokines and chemoattractant proteins in rheumatoid arthritis synovial fibroblasts through NF-κB dependent manner after TNFα stimulation [31]. The previous study concluded that miR-18a-5p is an enhancer of TNFα-induced cartilage destruction and chronic inflammation in the joint [31]. These published articles revealed that miR-18a-3p and miR-18a-5p might play a different role in arthritis. Moreover, the functions of a miRNA might be affected by its upstream or downstream genes. In the study revealing the miR-18a-3p/HOXA1 axis in OA [21], HOAX1 inhibits chondrocyte apoptosis and act as a protective role in OA progression; in the study revealing the enhancer role of miR-18a-5p in TNFαinduced cartilage destruction and chronic inflammation [31], NF-κB is an inducer of miR-18a-5p and NF-κB activation is known to be involved in many chronic inflammatory diseases [32]. In the current study, the target gene PDP1 is identified to promote inflammation in many diseases [33][34][35]. Thus, we suspected that the different role of upstream or downstream genes may affect the functions of miR-18a-3p and miR-18a-5p in arthritis. Here, we also investigated the functions of miR-18a-3p in ATDC5 cells after IL-1β treatment. We found that IL-1β-stimulated the increase in concentration of inflammatory cytokines and matrix metalloproteinases was attenuated by miR-18a-3p upregulation in ATDC5 cells. More importantly, miR-18a-3p alleviated the pathological changes of OA rats in in vivo experiments. In conclusion, miR-18a-3p inhibits OA progression by improving cartilage matrix remodeling and suppressing inflammation (Fig. 5).
MiRNAs are gene regulators that directly bind to 3′UTR of their mRNAs to degrade transcripts or suppress protein translation [36,37]. In the current study, PDP1 was identified as a target gene of miR-18a-3p and negatively regulated by miR-18a-3p. PDP1 is also called PDH, PDP, PDPC, PPM2A, PPM2C [38]. PDP1 overexpression leads to exhaustion of hematopoietic stem cells to increase the occurrence of myeloproliferative disorder [39]. Many studies revealed that induction of PDP1 expression is Notch-dependent, and PDP1 is involved in the activation of proinflammatory macrophages [33] and mouse hepatic macrophages [34]. PDP1 was also reported to function as an integral signaling target for proinflammatory stimuli (formyl-methionyl-leucyl-phenylalanine and leukotriene B4) and anti-inflammatory mediators (lipoxins) to regulate the activation of polymorphonuclear neutrophils in neutrophil proinflammatory responses [35]. Similarly, in this study, PDP1 upregulation reverses the inhibitory impact of miR-18a-3p upregulation on inflammatory cytokines in IL-1βstimulated ATDC5 cells. The association between PDP1 and MMPs has not been clearly reported yet. Here, we discovered that overexpressing PDP1 rescued the suppressive effect on protein levels of MMP2, MMP3 and MMP9 in IL-1β-stimulated ATDC5 cells. All these results suggested that PDP1 promotes inflammatory response in OA development, and miR-18a-3p inhibits inflammation in OA by targeting PDP1.
In the published article, NF-κB is an inducer of miR-18a in TNFα-induced rheumatoid arthritis synovial fibroblasts [31]. Additionally, NF-κB activation is the principal pathway of Notch signaling pathways, and PDP1 is a target of the Notch pathway and is activated by Notch [33,34]. The Notch pathway exerts a proinflammatory effect on OA [40]. Thus, we suspected that NF-κB or Notch signaling is associated with PDP1 expression in IL-1β-stimulated ATDC5 cells. However, whether NF-κB or Notch signaling is responsible for the downregulation of miR-18a-3p in IL-1β-stimulated ATDC5 cells and whether NF-κB or Notch signaling is involved in the miR-18a-3p/PDP1 axis still needs to be further investigated.
There are some limitations in our study. First, the present study lacked human biopsy examination to implicate the clinical relevance of our preclinical data. Second, the effects of PDP1 on chondrocytes and OA rats were not evaluated. Moreover, whether the miR-18a-3p/PDP1 axis is associated with the Notch pathway or NF-κB pathway in OA pathogenesis is still unknown. More relevant studies should be conducted in the future.
In conclusion, miR-18a-3p improves cartilage matrix remodeling and inflammation in OA by suppressing PDP1. Our study may offer a promising candidate for effective therapeutic method for OA progression.
Additional file 1: Table S1. Sequences of primers used for RT-qPCR.